Is it time to buy Cochlear?

Despite a new product release, Cochlear is among today’s worst performers on the S&P/ASX 200. Is it time to buy?

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Despite an announcement of the release of the new Nuclear 6 hearing implant product, Cochlear (ASX: COH) is today amongst the worst performers on the S&P/ASX 200 (ASX: XJO) (^AXJO), with shares trading at roughly a 13% discount following the company’s profit downgrade.

The world-leading manufacturer and distributor of cochlear implantable devices has today advised that profit for the second half would be lower than that of the immediately preceding six-month period, citing a combination of slowed US growth and customers waiting for the new model to be released.

The profit downgrade marks the second time in the space of four months that shareholders have been hit hard – which may be one of the reasons the market reacted so strongly to today’s news. Early in February, the company’s shares fell 9.3% in a single day’s trading in par with the release of their half-year accounts. In that report, the company announced a profit of $77.7 million – a fantastic result compared to its previous corresponding period – however, having failed to meet market expectations of hitting $80 million, investors slammed the shares.

Profit for the year is now expected to be between A$130 million and A$135 million, which would mean that the company’s second-half earnings would fall short of the $77.7 million profit reported in its first half.

However, what the market does not seem to have taken into account is the potential for future profitability. With the Nuclear 6 model set to be released in Canada and Korea very soon (whilst regulatory approval for sale in Europe is expected imminently and for America is expected by the end of the year), it is very likely that customers have been waiting it out for the new product to be released. Nuclear 6 reportedly contains ‘significant new functionality improving hearing performance and ease of use for cochlear implant recipients’.

Despite the bad news today, Cochlear remains one of Australia’s best healthcare businesses, along with CSL (ASX: CSL) and Resmed (ASX: RMD). Marking the company’s confidence for the future, Cochlear is anticipating paying at least $1.25 per share as a final dividend.

Foolish takeaway

The market appears to be feeling the effects of cold feet following the company’s most recent plunge, however, Cochlear’s products are arguably the best in the business. For investors focused on long-term gains, this plunge presents itself as a very attractive entry point. As customers begin to purchase the Nuclear 6 model, investors should start seeing significant gains.

In the market for high yielding ASX shares? Get “3 Stocks for the Great Dividend Boom” in our special FREE report. Click here now to find out the names, stock symbols, and full research for our three favourite income ideas, all completely free!

More reading

Motley Fool contributor Ryan Newman does not own shares in any of the companies mentioned in this article.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

asx share price competitions represented by businessmen arm wrestling
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

person reading news on mobile phone
⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »